This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q1 Earnings
by Ahan Chakraborty
LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q1 results as investor focus broadens beyond GLP-1s.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?
by Sundeep Ganoria
ABBV nears Q1 earnings with rising sales forecasts, but Humira erosion and weak ESP cloud outlook; can Skyrizi and Rinvoq momentum offset pressures?
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings-preview medical pharmaceuticals
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
by Kanishka Das
Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.
RGNXPositive Net Change MGTXNegative Net Change OCGNNegative Net Change
biotechs medical
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy
by Kanishka Das
Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.
SRPTPositive Net Change OCGNNegative Net Change
biotechs medical
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk
by Kanishka Das
Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.
SRPTPositive Net Change RGNXPositive Net Change OCGNNegative Net Change
biotechs medical
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
by Zacks Equity Research
RHHBY's Gazyva gets FDA review for lupus as strong trial data and pipeline wins across neurology and MS bolster growth outlook.
REGNPositive Net Change NVSPositive Net Change RHHBYPositive Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
by Ekta Bagri
ADMA banks on surging Asceniv demand to sustain growth, supported by expanded plasma supply and broader coverage, which should drive continued gains into 2026.
GRFSNegative Net Change ADMANegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
European Commission Approves MRNA's COVID-19-Influenza Combo Shot
by Zacks Equity Research
Moderna wins EU approval for its COVID-19-flu combo shot mCombriax, backed by strong phase III data showing superior immune response vs standalone vaccines.
SNYNegative Net Change GSKNegative Net Change MRNANegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
by Zacks Equity Research
Biogen gains after securing Greater China rights to felzartamab, giving it worldwide control as phase III studies advance in immune diseases.
NVSPositive Net Change BIIBPositive Net Change AGENPositive Net Change AMRNNegative Net Change
biotechs
NVO's Etavopivat Hits Key Goals in Phase III Sickle Cell Disease Study
by Zacks Equity Research
Novo Nordisk's etavopivat meets phase III goals, cutting VOCs and boosting haemoglobin in sickle cell disease, with data backing a favorable safety profile.
NVONegative Net Change INONegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals